Ed Kheder, MD
Department of Hospital Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2004 | Damascus University, Damascus, SY, Medicine, MD |
Postgraduate Training
| 2016-2018 | Clinical Fellowship, Investigation Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, Oakland University/William Beaumont School of Medicine, Royal Oak, Michigan |
| 2010-2011 | Clinical Fellowship, Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2009 | Clinical Residency, Hematology and Oncology Department, The University of Damascus, Damascus |
Licenses & Certifications
| 2024 | American Board of Internal Medicine, Internal Medicine |
| 2017 | Texas Medical License |
Experience & Service
Faculty Academic Appointments
Faculty, Washington University, St. Louis, MO, 2014 - 2016
Instructor, Siteman Cancer Center, St. Louis, MO, 2014 - 2016
Administrative Appointments/Responsibilities
Department of Hospital Medicine EHR Officer, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Faculty senate member, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
COVID-19-unit Inpatient Medical Director, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2020
Hospital Medicine Clinical & Research Conference Chair, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Other Professional Positions
Observer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2008
Observer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2007
Extramural Institutional Committee Activities
Member, Department of Hospital Medicine Norm and Branding Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Department of Hospital Medicine Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Department of Internal Medicine Education Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Acute and Critical Care subcommittee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Internal Medicine and Cancer Survivorship Ground Rounds Planning Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Chair, General Internal Medicine Clinical & Research Conference Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, GME Diversity and Disparities Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2023
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Cancer Prevention: MD Anderson Guidelines. Oral Presentation. Conference. Cancer Prevention: MD Anderson Guidelines. Oral Presentation. Houston, TX, US.
Regional Presentations
- 2013. A Rare Case of Bilateral Progressive Vision Loss:Neurosarcoidosis. Conference. A Rare Case of Bilateral Progressive Vision Loss:Neurosarcoidosis. Troy, MI, US.
National Presentations
- 2017. Detection of circulating antibodies against KRAS in patients with advanced cancers. Conference. AACR, US.
- 2014. Be Aware of the Triad: Depression, Diabetes Mellitus, Weight Loss. Conference. ACP, US.
- 2013. Rare Case of Bilateral Progressive Vision Loss: Neurosarcoidosis. Conference. ACP, US.
Selected Publications
Peer-Reviewed Articles
- Manzano JM, Sahar H, Aldrich J, Lu M, Shoukier M, Peterson CB, Dickson K, Koom-Dadzie K, Kheder E, Franco Vega MC, Mohammed A, Muthu M, Simbaqueba C, Senechalle MS, Brito-Dellan N. Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service. Support Care Cancer 32(3):160, 2024. e-Pub 2024. PMID: 38366007.
- Leung CK, Walton NC, Kheder E, Zalpour A, Wang J, Zavgorodnyaya D, Kondody S, Zhao C, Lin H, Bruera E, Manzano JM. Understanding Potentially Preventable 7-day Readmission Rates in Hospital Medicine Patients at a Comprehensive Cancer Center. Am J Med Qual 39(1):14-20, 2024. e-Pub 2024. PMID: 38127668.
- Manzano JM, Muthu M, Kheder E, Mohammed A, Halm J, Dickson K, Ali N, Leung C, Koom-Dadzie K, Rubio D, Odaro O, Sibille M, Etchegaray M, Wilson K, Lin H, George M. Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center. Support Care Cancer 30(9):7783-7788, 2022. e-Pub 2022. PMID: 35705751.
- Manzano JM, Muthu M, Kheder E, Mohammed A, Halm J, Dickson K, Ali N, Leung C, Koom-Dadzie K, Rubio D, Odaro O, Sibille M, Etchegaray M, Wilson K, Lin H, George M. Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center. Support Care Cancer, 2022. e-Pub 2022. PMID: 35705751.
- Alshawa A, Gong J, Marcott V, Khan R, Boving V, Brown L, Beno J, Kheder E, Fu S. Strategic improvement of oral antineoplastic investigational agents compliance. Global Journal on Quality and Safety in Healthcare 2(1):5-10, 2019. e-Pub 2019.
- Lipe DN, Elsayem A, Cruz-Carreras MT, Thomas J, Feliciano A, Ren J, Gaeta SM, Rajha E, Manasanch E, Kheder E, Brock P, Reyes-Gibby C. Characteristics of cancer patients with COVID-19 in a cancer hospital. Ann Palliat Med 10(2):1763-1771, 2018. e-Pub 2018. PMID: 33222454.
- Kheder ES, Hong DS. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res, 2018. e-Pub 2018. PMID: 29986850.
- Kouri Abdalla R, Kheder E, Yeow R, Ginoya Meka S, Yaldo O, Abbas EA. The impact of statin therapy on survival for in hospital cardiac arrest. J Investig Med 65(7):e4, 2017. e-Pub 2017. PMID: 28824004.
- Ed K. Questions and Answers in Renal Disease and Electrolytes Abnormalities. Article for School of Medicine Damascus University, 2004. e-Pub 2004.
Abstracts
- Nguyen SV, Stephen BA, Curry SL, Halm J, Kheder E. Inpatient Outcomes of New Solid Tumor Oncology Patients Admitted to a Comprehensive Cancer Center, 2024. e-Pub 2024.
- Ed K, Saji L, Iyre R, Harris L, Michaud L, George M, Mandayam S. Improving Medication Reconciliation Rate Within 24 Hours of Admission at a Comprehensive Cancer Center. SHM Converge, 2023. e-Pub 2023.
- Leung C, Walton N, Ed K, Zalpour A, Wang J, Zavgorodnyaya D, Kondody S, Zhao C, Lin H, Bruera E, Manzano J. Understanding Preventable 7-day Readmission Rates in Hospital Medicine Patients at a Comprehensive Cancer Center. SHM Converge, 2023. e-Pub 2023.
- Ali N, Ed K, Dickson K, Rubio D, Koom-Dadzie K, Edelkamp P, Lin HY, Muthu M, Mohammed A, Leung C, Odaro O, Sibille M, George MC, Halm J, Manzano JM. Association of presenting symptoms with COVID-19 disease severity and outcomes among hospitalized patients with cancer and COVID-19. ASCO 2023- online publication, 2023. e-Pub 2023.
- Manzano JG, Halm J, Muthu M, et al KE. Hospitalization Characteristics and Outcomes of Patients with Cancer and COVID-19. Presented as an oral proffered paper at the 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer, 2021. e-Pub 2021.
- Ed K. Improving admission medication reconciliation among general internal medicine patients in a tertiary cancer center. ASCO, 2021. e-Pub 2021.
- Ed K. Immune checkpoint inhibitor (ICI)-related pneumonitis among patients with lung cancer admitted to an Oncology Hospitalist Service: Treatment patterns and hospitalization outcomes. ASCO, 2021. e-Pub 2021.
- Ed K. Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact. Journal of Clinical Oncology, 2018. e-Pub 2018.
- Xing Y, Guo Y, Ning Chang JC, Patel TA, Kheder E, Meric-Bernstam F, Shih YT. Off-label use of everolimus and associated factors in non-elderly cancer patients with private insurance in the United States, 2018. e-Pub 2018.
- Ed K. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. Journal of Clinical Oncology, 2018. e-Pub 2018.
- Ed K. Detection of circulating antibodies against KRAS in patients with advanced cancers. Cancer Research, 2017. e-Pub 2017.
- Ed K. Be Aware of the Triad: Depression, Diabetes Mellitus, Weight Loss. ACP, American College of Physicians/Internal Medicine, 2014. e-Pub 2014.
- Ed K. Higher Bone Marrow Lymphocyte Percentage 3 to 6 Month After Therapy with Hypercvad +Dasatinib Than That with Hypercvad +Imatinib or Hypercvad Alone In Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. American Society of Hematology (ASH)(4336), 2010. e-Pub 2010.
Book Chapters
- Karp D, Wolters Kluwer GSF. MAP Kinase Pathway Section. In: Handbook of Targeted Cancer Therapy and Immunotherapy, pp(223-229), 2022.
- Karp D, Wolters Kluwer GSF. MAP Kinase Pathway Section. In: Handbook of Targeted Cancer Therapy, pp(124-148), 2018.
Patient Reviews
CV information above last modified December 19, 2025